USANA Health Sciences (NYSE:USNA) Insider Sells $75,137.62 in Stock

Key Points

• Insider sale: Director Joshua Foukas sold 3,791 shares on May 7 at $19.82 for $75,137.62, after selling 4,461 shares on Feb. 20 at $21.34 (SEC Form 4 filings).
• Strong quarter and guidance: USANA beat Q1 estimates with $0.61 EPS (vs. $0.44 expected) and $250.2M revenue, and set FY2026 guidance of 1.950–2.290 EPS (analysts’ consensus ~1.95).
• Mixed analyst sentiment but negative consensus: Several firms cut ratings and MarketBeat shows a consensus of "Reduce," though Sidoti raised its FY2026 estimate to $2.12 and Zacks upgraded the stock.

USANA Health Sciences, Inc. (NYSE:USNA - Get Free Report) insider Joshua Foukas sold 3,791 shares of the stock in a transaction that occurred on Thursday, May 7th. The stock was sold at an average price of $19.82, for a total value of $75,137.62. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Joshua Foukas also recently made the following trade(s):

• On Friday, February 20th, Joshua Foukas sold 4,461 shares of USANA Health Sciences stock. The stock was sold at an average price of $21.34, for a total value of $95,197.74.

USANA Health Sciences Price Performance

NYSE USNA traded down $0.37 during midday trading on Friday, hitting $19.09. 51,239 shares of the company traded hands, compared to its average volume of 124,878. The company has a market cap of $352.46 million, a PE ratio of 40.56, a price-to-earnings-growth ratio of 0.86 and a beta of 0.77. The company's 50-day simple moving average is $18.45 and its 200-day simple moving average is $19.70. USANA Health Sciences, Inc. has a 52 week low of $16.60 and a 52 week high of $38.32.

USANA Health Sciences (NYSE:USNA - Get Free Report) last announced its earnings results on Tuesday, May 5th. The company reported $0.61 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.44 by $0.17. The business had revenue of $250.22 million for the quarter, compared to analysts' expectations of $240.99 million. USANA Health Sciences had a return on equity of 6.21% and a net margin of 0.96%.USANA Health Sciences has set its FY 2026 guidance at 1.950-2.290 EPS. On average, research analysts predict that USANA Health Sciences, Inc. will post 1.95 earnings per share for the current year.

Analyst Ratings Changes

A number of analysts have recently weighed in on USNA shares. Zacks Research cut USANA Health Sciences from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, April 22nd. Wall Street Zen cut USANA Health Sciences from a "buy" rating to a "hold" rating in a research report on Saturday, May 2nd. Finally, Weiss Ratings reissued a "sell (d)" rating on shares of USANA Health Sciences in a research report on Friday, March 27th. One research analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat, the stock presently has a consensus rating of "Reduce".

Hedge Funds Weigh In On USANA Health Sciences

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Pzena Investment Management LLC raised its stake in USANA Health Sciences by 1.2% in the 3rd quarter. Pzena Investment Management LLC now owns 1,212,588 shares of the company's stock worth $33,407,000 after acquiring an additional 14,328 shares during the last quarter. Renaissance Technologies LLC raised its stake in USANA Health Sciences by 1.9% in the 4th quarter. Renaissance Technologies LLC now owns 1,147,323 shares of the company's stock worth $22,522,000 after acquiring an additional 21,793 shares during the last quarter. Vanguard Group Inc. raised its stake in USANA Health Sciences by 5.7% in the 3rd quarter. Vanguard Group Inc. now owns 1,069,032 shares of the company's stock worth $29,452,000 after acquiring an additional 57,249 shares during the last quarter. Dimensional Fund Advisors LP raised its stake in USANA Health Sciences by 1.9% in the 3rd quarter. Dimensional Fund Advisors LP now owns 915,049 shares of the company's stock worth $25,210,000 after acquiring an additional 17,318 shares during the last quarter. Finally, Nantahala Capital Management LLC purchased a new position in shares of USANA Health Sciences during the 4th quarter valued at about $11,485,000. Hedge funds and other institutional investors own 54.25% of the company's stock.

Trending Headlines about USANA Health Sciences

Here are the key news stories impacting USANA Health Sciences this week:

• Positive Sentiment: Sidoti raised its FY2026 EPS estimate for USANA to $2.12 from $1.95, signaling improved earnings expectations and potentially supporting a higher valuation. USANA Health Sciences stock page
• Positive Sentiment: Zacks upgraded USANA to a Rank #2 (Buy), reflecting stronger optimism around the company’s earnings outlook and estimate revisions. Zacks upgrade article
• Positive Sentiment: Recent earnings-related coverage highlighted a large EPS beat for the quarter, suggesting USANA’s operating results have been better than expected. Yahoo Finance EPS beat article
• Positive Sentiment: USANA’s Q1 earnings snapshot and call transcript point to a solid quarter and a confident growth outlook for 2026, which can help sentiment. TipRanks growth path article
• Neutral Sentiment: The company earned a spot on USA TODAY’s Top Workplaces list, a positive branding and culture headline but unlikely to move the stock materially on its own. PR Newswire workplace award article
• Neutral Sentiment: Multiple articles recapped USANA’s latest earnings and management commentary; these reinforce the post-earnings narrative but are mostly follow-up coverage. Q1 earnings snapshot article
• Negative Sentiment: Insider Joshua Foukas sold 3,791 shares at $19.82, which can create some caution even though the dollar amount was modest. SEC Form 4 filing

USANA Health Sciences Company Profile

USANA Health Sciences, Inc is a Utah‐based company that develops, manufactures and distributes nutritional supplements and personal care products through a network of independent distributors. Founded in 1992 by Dr. Myron Wentz, the company's portfolio includes vitamins, minerals, dietary supplements, weight‐management products and skin‐care formulations. USANA's products are formulated in its own laboratories to meet pharmaceutical‐grade standards, and the company has invested heavily in research and development and quality control to support its offerings.

Operating primarily through a direct selling model, USANA serves markets in North America, Asia Pacific, Europe and Latin America.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.